Linx denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for linx are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied the LINX Device as Experimental

Cigna's experimental or investigational denial means the reviewer applied a coverage policy concluding that the LINX Reflux Management System has not met Cigna's internal evidence standard for routine clinical use in your specific clinical context. This category of denial is one of the most commonly overturned on external review, because the LINX device received FDA premarket approval and has an established body of peer-reviewed evidence supporting its use in appropriate GERD patients who have failed medical management.

## Why This Denial Is Appealable

An experimental denial based on a coverage policy that does not reflect current FDA clearance status or published evidence is challengeable on both factual and procedural grounds. Your appeal should document the FDA approval status of the device (obtainable directly from the FDA device database at fda.gov), reference applicable guideline society endorsements (e.g., SAGES) generically, and argue that Cigna's policy is inconsistent with the established medical evidence. If Cigna's policy uses a specific evidence-rating framework, your prescriber's letter should address each element of that framework.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your denial notice (commonly 180 days for ERISA plans). Request the specific clinical criteria and coverage policy number Cigna applied so you can respond point by point.
• External review: Under ACA §2719 and applicable state external review laws, experimental/investigational denials are expressly eligible for independent external review. The general window is 4 months from final internal denial — verify your exact deadline on your Explanation of Benefits.
• Expedited option: If your condition is urgent, request expedited external review for a faster decision, typically within 72 hours of the IRO receiving a complete file.

## Documentation to Gather

1. FDA clearance documentation — print the FDA 510(k) or PMA clearance page for the LINX device directly from fda.gov and include it as an exhibit. 2. Diagnosis confirmation — pH monitoring, impedance testing, endoscopy, or manometry results establishing objective GERD refractory to medical therapy. 3. Failed medical management — a dated log of all acid-suppression and other therapies tried, with documented outcomes and reasons for failure or intolerance. 4. Clinical severity — chart notes documenting symptom burden, quality-of-life impact, and any complications. 5. Prescriber medical-necessity letter — must address Cigna's specific evidentiary criteria and explain why this patient's case fits within the established indications. 6. Guideline references — ask your gastroenterologist or surgeon to reference current applicable society guidelines by organization name (not specific numbers).

## Criteria-Mapping Structure

Obtain Cigna's exact coverage policy language (you are entitled to this under ERISA or ACA). List each criterion or evidence threshold Cigna states. For each: cite the FDA clearance record, the chart finding, or the guideline society statement that satisfies it. If Cigna's policy predates current evidence, note the policy's last-review date and contrast it with more recent published evidence your physician can identify. This structured response is the foundation of a successful reversal.